CoChat

Short-course adjunctive gentamicin as empirical therapy in patients with severe sepsis and septic shock: A prospective observational cohort study.

Open access
Ong, David S. Y., Frencken, Jos F., Klein Klouwenberg, Peter M. C., Juffermans, Nicole, van der Poll, Tom, Bonten, Marc J. M., Cremer, Olaf L. · 2017 · Clinical Infectious Diseases

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

BACKGROUND.: Metaanalyses failed to demonstrate clinical benefits of beta lactam plus aminoglycoside combination therapy compared to beta lactam monotherapy in patients with sepsis. However, few data exist on the effects of short-course adjunctive aminoglycoside therapy in sepsis patients with organ failure or shock. METHODS.: We prospectively enrolled consecutive patients with severe sepsis or septic shock in 2 intensive care units in the Netherlands from 2011 to 2015. Local antibiotic protocols recommended empirical gentamicin add-on therapy in only 1 of the units. We used logistic regression analyses to determine the association between gentamicin use and the number of days alive and free of renal failure, shock, and death, all on day 14. RESULTS.: Of 648 patients enrolled, 245 received gentamicin (222 of 309 [72%] in hospital A and 23 of 339 [7%] in hospital B) for a median duration of 2 days (interquartile range, 1-3). The adjusted odds ratios associated with gentamicin use were 1.39 (95% confidence interval [CI], 1.00-1.94) for renal failure, 1.34 (95% CI, 0.96-1.86) for shock duration, and 1.41 (95% CI, 0.94-2.12) for day-14 mortality. Based on in vitro susceptibilities, inappropriate (initial) gram-negative coverage was given in 9 of 245 (4%) and 18 of 403 (4%) patients treated and not treated with gentamicin, respectively (P = .62). CONCLUSIONS.: Short-course empirical gentamicin use in patients with sepsis was associated with an increased incidence of renal failure but not with faster reversal of shock or improved survival in a setting with low prevalence of antimicrobial resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/cix186

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. Nethmap: consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in The Netherlands in 2015
  2. SWAB, 2010, Guidelines for antibacterial therapy of adult patients with sepsis

Cited by

See all 109

Metadata

Authors
Ong, D. S. Y., Frencken, J. F., Klein Klouwenberg, P. M. C., Juffermans, N., van der Poll, T., Bonten, M. J. M., & Cremer, O. L.
Affiliations
  • University Medical Center Utrecht (NL)
  • Amsterdam UMC Location University of Amsterdam (NL)
Venue
Clinical Infectious Diseases
Published
2017-04-15
Volume
64
Issue
12
Pages
1731-1736
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2594782125
Cited by
109
References
21
Citations by year
2026: 5 · 2025: 10 · 2024: 13 · 2023: 8 · 2022: 10 · 2021: 18 · 2020: 19 · 2019: 10 · 2018: 9 · 2017: 7
FWCI
9.64
Type
journal article
Language
en
Open access
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (acceptedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • Utrecht University Repository (Utrecht University) (submittedVersion)
Funders
Center for Translational Molecular Medicine (04I-201)
Topics
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
gentamicin, sepsis, septic shock, empirical antibiotic therapy, renal failure, shock reversal, mortality, antimicrobial resistance, beta-lactam therapy
MeSH terms
Aged, Anti-Bacterial Agents, Female, Gentamicins, Gram-Negative Bacteria, Humans, Intensive Care Units, Male, Middle Aged, Multiple Organ Failure, Prospective Studies, Shock, Septic, Cohort Studies, Logistic Models, Hospital Mortality, Sepsis, Drug Resistance, Multiple, Bacterial, Tertiary Care Centers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.